TY - JOUR
T1 - Tumour-on-a-chip
T2 - Microfluidic models of tumour morphology, growth and microenvironment
AU - Tsai, Hsieh Fu
AU - Trubelja, Alen
AU - Shen, Amy Q.
AU - Bao, Gang
N1 - Funding Information:
This work was supported in part by the Cancer Prevention and Research Institute of Texas (RR140081 to G.B.). H.F.T. and A.Q.S. acknowledge financial support from the OIST Graduate University with subsidy funding from the Cabinet Office, Government of Japan. H.F.T. was in addition supported by a JSPS Research Fellowship for Young Scientists (DC1) and a JSPS Grant in Aid for JSPS Fellows (JP1700362).
Publisher Copyright:
© 2017 The Author(s) Published by the Royal Society. All rights reserved.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Cancer remains one of the leading causes of death, albeit enormous efforts to cure the disease. To overcome the major challenges in cancer therapy, we need to have a better understanding of the tumour microenvironment (TME), as well as a more effective means to screen anti-cancer drug leads; both can be achieved using advanced technologies, including the emerging tumour-on-a-chip technology. Here, we review the recent development of the tumour-on-a-chip technology, which integrates microfluidics, microfabrication, tissue engineering and biomaterials research, and offers new opportunities for building and applying functional three-dimensional in vitro human tumour models for oncology research, immunotherapy studies and drug screening. In particular, tumour-on-a-chip microdevices allow well-controlled microscopic studies of the interaction among tumour cells, immune cells and cells in the TME, of which simple tissue cultures and animal models are not amenable to do. The challenges in developing the next-generation tumour-on-a-chip technology are also discussed.
AB - Cancer remains one of the leading causes of death, albeit enormous efforts to cure the disease. To overcome the major challenges in cancer therapy, we need to have a better understanding of the tumour microenvironment (TME), as well as a more effective means to screen anti-cancer drug leads; both can be achieved using advanced technologies, including the emerging tumour-on-a-chip technology. Here, we review the recent development of the tumour-on-a-chip technology, which integrates microfluidics, microfabrication, tissue engineering and biomaterials research, and offers new opportunities for building and applying functional three-dimensional in vitro human tumour models for oncology research, immunotherapy studies and drug screening. In particular, tumour-on-a-chip microdevices allow well-controlled microscopic studies of the interaction among tumour cells, immune cells and cells in the TME, of which simple tissue cultures and animal models are not amenable to do. The challenges in developing the next-generation tumour-on-a-chip technology are also discussed.
KW - Drug screening
KW - Microfluidics
KW - Tumour microenvironment
KW - Tumour-on-a-chip
UR - http://www.scopus.com/inward/record.url?scp=85023181968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023181968&partnerID=8YFLogxK
U2 - 10.1098/rsif.2017.0137
DO - 10.1098/rsif.2017.0137
M3 - Review article
C2 - 28637915
AN - SCOPUS:85023181968
VL - 14
JO - Journal of the Royal Society Interface
JF - Journal of the Royal Society Interface
SN - 1742-5689
IS - 131
M1 - 20170137
ER -